 | Up a level |
Buse, JB; Rosenstock, J; Sesti, G; Schmidt, WE; Montanya, E; Brett, JH; Zychma, M; Blonde, L; Ahmed, A; Alvarsson, M; Anderson, C; Aoki, A; Aranko, S; Bailey, B; Barbonta, D; Baur, C; Bednarczyk-Kaluzny, M; Blevins, T; Blonde, L; Bode, B; ... (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 374(9683), pp. 39-47. London: Elsevier 10.1016/S0140-6736(09)60659-0
Marre, M; Shaw, J; Brändle, M; Bebakar, WM; Kamaruddin, NA; Strand, J; Zdravkovic, M; Le, Thi TD; Colagiuri, S; De Loredo, L; Waitman, J; Litwak, L; Rodriguez, M; Vines, G; Maffei, L; Issa, C; Lowy, A; Bartley, P; Kamp, M; Shaw, J; ... (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine, 2009(26(3)), pp. 268-78. Chichester: Wiley 10.1111/j.1464-5491.2009.02666.x
